Physician profile
Michael S Sellman
NPI 1104870104
$4,086.88
in general payments reported to CMS, 2019-2025
11 companies · $681 in 2025
The $681 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $511 · 2021: $699 · 2022: $735 · 2023: $618 · 2024: $346 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,919.73 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $952.30 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Genzyme Corporation | $407.74 | 2019-2022 | |
| Eisai INC. | $330.94 | 2024-2025 | |
| Horizon Therapeutics Plc | $314.38 | 2022-2023 | Uplizna |
| Lilly USA, LLC | $58.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.00 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $22.97 | 2021 | |
| Lundbeck LLC | $22.91 | 2023 | Vyepti |
| Amgen INC. | $19.08 | 2020 | |
| Allergan, INC. | $13.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.